Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jury out on UK gene screening and prenatal testing:

This article was originally published in Clinica

Executive Summary

The degree of current and prospective growth in the use of prenatal genetic testing has led the UK's Human Genetics Commission (HGC) to conclude that further consideration is needed to best regulate the technology. In a milestone report, published last week, the commission said it would also monitor developments in national screening programmes. The 180-page report, "Inside Information - Balancing interests in the use of personal genetic data", puts the human subject at the top of the agenda. It is evidence of the growing awareness in the medical and clinical research communities of the high degree of sensitivity surrounding genetics, and the realisation that scientific progress involving the technology is inextricably dependent on the public's confidence in the system that regulates it. The HGC makes a range of recommendations concerning the need to adapt UK primary and secondary legislation to tighten this, and for the users of genetic information to become more closely involved with the scientific community.

You may also be interested in...

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says

As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.

Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia

Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts